Validation of a 22-Gene Genomic Classifier in Patients With Recurrent Prostate Cancer

Overview of attention for article published in JAMA Oncology, April 2021

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (95th percentile)

Mentioned by

news: 28 news outlets
blogs: 3 blogs

twitter: 89 X users
guideline: 1 clinical guideline source

Readers on

mendeley: 119 Mendeley

So far, Altmetric has seen 4 posts from 3 blogs.

22-Gene Genomic Classifier for Recurrent Prostate Cancer

Physician's Weekly, 06 May 2021

Decipher Biosciences Inc. (Decipher) is a genomic classifier (GC) that could help estimate the risk of distant metastasis (DM…

Hormone Therapy for Prostate Cancer? A Genetic Test Could Help Decide

Cancer Currents: An NCI Cancer Research Blog, 15 Mar 2021

For some men with prostate cancer, a genetic biomarker test called Decipher may help predict if their cancer will spread…

Genomics week in brief: Week ending 13th February

Front Line Genomics, 15 Feb 2021

The latest ‘Genomics week in brief’ filled with the most recent genomics news and research from the past week! Top stories…

Prostate Cancer: Multigene Biomarker Validated as Prognostic/Predictive Test

Physician's Weekly, 12 Feb 2021

Genomic classifier helps weed out men less likely to benefit from added hormone…

This page shows the most recent blog posts that mention this research output. Click here to find out how to access more activity.